DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Genetic Technology-Life Science Trends across Drug Development for Central Nervous System Disorders" report to their offering.
This edition of Genetic Technology depicts the current landscape and the new life sciences trends across schizophrenia and other central nervous system (CNS) disorders. Specific products developed to target chronic CNS disorders, including the use of cell therapeutics and autoimmune approaches, are profiled. Additionally, analyst insights and strategic perspectives for business development across neurological diseases are presented, along with the intellectual property scenario around therapeutics for CNS disorders.
The Genetic Technology TechVision Opportunity Engine (TOE) presents the latest R&D developments and advances with an emphasis on opportunities to profit in the explosive field of genetic technology through technology transfer, joint ventures, and acquisitions. The complete gamut of genetic technology applications is covered including the latest developments in omics technologies; genetic, cellular, and alternative therapies; sequencing technologies; and genetically altered animals and plants.
The Health & Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nano-medicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare.
Key Topics Covered:
- Trend-based Technology Profiles
- Strategic Perspectives
For more information about this report visit http://www.researchandmarkets.com/research/pbrx8q/genetic